Safety Analysis of Fidaxomicin in Comparison With Oral Vancomycin for Clostridium difficile Infections.

2012·0.1 MB·English

by  Weiss, Karl

SUPPLEMENT ARTICLE
Safety Analysis of Fidaxomicin in Comparison
Clostridium difficile
With Oral Vancomycin for
Infections
KarlWeiss,1RobinL.Allgren,2andSarahSellers3
1DepartmentofInfectiousDiseasesandMicrobiology,Maisonneuve-RosemontHospital,FacultyofMedicine,UniversityofMontreal,Quebec,Canada;
2BreakthroughBioDevelopment,LLC,SanDiego,California,and3q-Vigilance,LLC,Barrington,Illinois
FidaxomicinisanovelmacrocyclicantibioticrecentlyapprovedbytheUSFoodandDrugAdministrationfor
the treatment of Clostridium difficile–associated diarrhea in adults. We reviewed safety datafrom nonclinical
studies and clinical trials (phases 1, 2A, and 3) with fidaxomicin. In nonclinical studies, fidaxomicin was
administered orally at approximately 1g/kg/d to dogs for up to 3 months with no significant target-organ
toxicities observed. A total of 728 adults have received oral fidaxomicin in clinical trialsto date: 116 healthy
volunteers and 612 patients with C. difficile infection. In phase 3 clinical trials, fidaxomicin was well toler-
ated, with a safety profile comparable with oral vancomycin. There were no differences in the incidence of
death or serious adverse events between the 2 drugs. Fidaxomicin appears to be well tolerated. Continued
monitoring of adverse events in the postmarketing setting will provide additional information about the full
safetyprofileoffidaxomicin.
Clostridium difficile was recognized as the causative 1995, the Centers for Disease Control and Prevention
agent for antibiotic-associated colitis in 1978 [1], recommended that vancomycin not be used orally for
first observed in conjunction with clindamycin treat- CDI in hospital settings as a strategy to prevent the
ment [2]. Since then, C. difficile infection (CDI) has emergence of VRE and vancomycin intermediate Sta-
become an increasingly challenging nosocomial infec- phylococcusaureus.
tionwithseveremedicalconsequences[3–6]. Priortotheapprovaloffidaxomicin,oralvancomy-
Hamster animal models showed some protective cin was the only agent approved by the US Food and
and beneficial effect from oral vancomycin, which Drug Administration (FDA) for the treatment of anti-
quickly became the treatment drug of choice [7, 8]. biotic-associated pseudomembranous colitis produced
However, the use of all vancomycin formulations by C. difficile. Metronidazole was subsequently used
(parvules and intravenous vancomycin used orally) off-label and, as a much less expensive alternative,
hadtobelimitedeitherbecauseofitshighprice(par- became the de facto first-line treatment for mild to
vules)ortocurtailthepotentialriskfortheemergence moderate cases of CDI [8,10].Other antibiotics have
of vancomycin-resistant enterococci (VRE) [9]. In been tried in the past (fusidic acid, bacitracin, rifaxi-
min, and nitazoxanide), but only limited clinical data
are available for the treatment of CDI [11]. Thus,
Correspondence: Karl Weiss, MD, FRCPC, Maisonneuve-Rosemont Hospital, there has been a need for new therapies to treat this
5415L’Assomption,Montreal,QC,CanadaH1T2M4([email protected]).
challengingdisease.
ClinicalInfectiousDiseases 2012;55(S2):S110–15 Ideally, drugs against C. difficile should be mini-
©TheAuthor2012.PublishedbyOxfordUniversityPressonbehalfoftheInfectious
DiseasesSocietyofAmerica.Allrightsreserved.ForPermissions,pleaseemail: mally absorbed, remain in the intestinal lumen, and
[e-mail]edistributedunder
have a narrow spectrum of activity, preserving the
thetermsoftheCreativeCommonsAttributionNon-CommercialLicense(http://
creativecommons.org/licenses/by-nc/3.0), which permits unrestricted non- normalmicrobiotaofthegut.
commercialuse,distribution,andreproductioninanymedium,providedtheoriginal Fidaxomicin has a narrow-spectrum antibacterial
workisproperlycited.
DOI:10.1093/cid/cis390 profile, with potent bactericidal activity specifically
(cid:129) (cid:129)
S110 CID 2012:55 (Suppl2) Weissetal
againstC.difficile.Itdisplaysmoderateinvitroactivityagainst (half maximal inhibitory concentration greater than the
someGram-positivebacteria(S.aureusandEnterococcusspp.) highestnominaldosetestedof10µg/mL).
and is inactive against Gram-negative organisms and yeast. Thepotentialforreproductivetoxicitywasassessedinafer-
Fidaxomicin is minimally absorbed from the gastrointestinal tilitystudyinratsandembryo-fetaldevelopmentstudiesinrats
(GI) tract, with plasma concentrations in the nanogram-per- and rabbits. Fidaxomicin did not affect the fertility of male
milliliterrangeafteroraldosing. and female ratsatintravenousdosesof6.3mg/kg,resultingin
In2phase3trials,fidaxomicindemonstratednoninferiority systemic exposure approximately 100 times that in humans.
to vancomycin for clinical response in the treatment of CDI Fidaxomicin at the highest dose tested in rats (15mg/kg/d)
and superiority to vancomycin for sustained clinical response andrabbits(7.5mg/kg/d)exhibitednomaternal,reproductive,
(curewithout recurrence during the30-dayfollow-up period). orembryo-fetaldevelopmentaltoxicity.
The efficacy results are presented in detail elsewhere [12,13]. Thegenotoxicityoffidaxomicinwasassessedininvitro(bac-
The safety results from nonclinical and clinical studies are terial reverse mutation and chromosomal aberration assays)
summarizedinthefollowingsections. and in vivo (rat micronucleus assay) studies. Additionally, the
mainactive metabolite OP-1118 was evaluated for genotoxicity
in vitro (bacterial reverse mutation and chromosomal aberra-
NONCLINICALSAFETYSTUDIES tionassays).Overall,resultsfromgenotoxicitytestsshowedthat
fidaxomicin is not expected to be genotoxic in humans. Long-
A standard battery of nonclinical studies was conducted to term carcinogenicitystudieshave notbeenconducted toevalu-
assess the safety of fidaxomicin, including general toxicity atethecarcinogenicpotentialoffidaxomicin.
(acute and repeated dose for up to 3 months), safety pharma-
cology,reproductivetoxicity,andgenotoxicitystudies[13]. SAFETYPROFILEINCLINICALTRIALS
For a single intravenous fidaxomicin dose in rats, the 50%
lethaldosewasapproximately200mg/kgandthenoobserved During the clinical development of fidaxomicin, 728 subjects
adverse effect level(NOAEL) was determinedto be62.5mg/kg; received fidaxomicin: 116 healthy adult volunteers in phase 1
at this NOAEL dose, the peak plasma level of fidaxomicin was studies and 612 adults with CDI in phase 2A and 3 studies.
3000–10200ng/mL, which is at least 300-fold higher than the In the phase 1 and 2A studies, subjects were exposed to doses
maximum concentration observed in humans. The toxicity of of fidaxomicin ranging 100–450mg. No significant dose-
fidaxomicin was also evaluated in a repeated-dose setting in relatedadverseevents(AEs)wereobserved[14,15].
rats and monkeys at oral doses up to 90mg/kg/d for 28 days; The safety and efficacy of fidaxomicin were compared with
there were no drug-related deaths or effects on clinical oral vancomycin in 2 randomized, double-blinded pivotal
observations. In a 3-month study in dogs, the NOAEL oral phase 3 studies. One was performed in North America [12],
dose was the highest dose of 9.6g/d (equivalent to 94–1160 and the other was performed in both North America and
mg/kg/d). Although some emesis and soft stools were observed Europe [13]. In both phase 3 studies, fidaxomicin was admin-
at the highest doses in this study, these were attributed to the istered orally at 200mg every 12 hours for 10 days, and van-
very large doses delivered (5%–7% of daily food intake). They comycin was administered orally at 125mg every 6 hours for
were not exacerbated with continued dosing and were not 10 days (the currently recommended dose for nonfulminant
associated with changes in food consumption or weight gain disease). In these studies, 564 subjects with CDI were treated
betweengroups or with histological changes. Thisindicatesthat with fidaxomicin and 583 were treated with vancomycin,
high fecal levels of fidaxomicin (up to milligram-per-gram respectively.Overall,86.7%ofsubjectscompletedafullcourse
levels) are not associated with GI toxicity. None of these oftreatment.
studies revealed evidence of toxicity to the bone marrow/ Ofthe1147subjectsevaluableforthepooledphase3safety
hematopoietic system,liver,kidney, orother targetorgan. analysis, 567 (49.4%) were aged ≥65 years (272 treated with
The hERG channel, a potassium ion channel, mediates the fidaxomicin and 295 treated with vancomycin), reflecting that
repolarizing currentinthecardiacactionpotential.Whenthis the elderly are disproportionately affected by CDI. Subjects
channel’s ability to conduct electrical current across the cell were mainly white (90%), female (58%), and in-patients
membrane is inhibited or compromised, by either drugs or (64%). Many subjects enrolled in the phase 3 program were
rare mutations in some families, it can result in a potentially acutely ill, with concomitant acute and chronic medical con-
fatal disordercalled long-QT syndrome. An in vitro assay has ditionsinadditiontoCDI.
beenestablishedtoscreendrugsforhERGinhibition. Intheseclinicalstudies,thesafetyprofileoffidaxomicinwas
In vitro, neither fidaxomicin nor its main metabolite OP- comparable with that of the active comparator vancomycin.
1118 had an inhibitory effect on the hERG channel current For example, the total number of deaths in the phase 3 trials
(cid:129) (cid:129)
SafetyAnalysisofFidaxomicin CID 2012:55 (Suppl2) S111
wassimilarforfidaxomicin(36of564;6.4%)andvancomycin subjects had other risk factors for GI bleeding, such as recent
(38of583;6.5%;P=notsignificant).Noneofthesedeathswas bowel surgery, coagulopathies, or concomitant medications
believedtobeduetostudydrugtoxicity,buttheywereattribu- with anticoagulant properties. For fidaxomicin subjects, the
tedtothesubject’s significantunderlying morbidities. Nine of early GI bleeding events tended to be mild self-limited events
the deaths were deemed possibly related to progression of the (such as a single bloody bowel movement or intermittent
underlying CDI: 5 for fidaxomicin and 4 for vancomycin bleeding from preexisting rectal hemorrhoids) not requiring
(5 men, 4 women; mean days on therapy, 6.78). In terms of intervention. Fidaxomicin was not associated with an increase
any serious AEs (SAEs) or general AEs, the overall rates also inbleedingeventsinother(non-GI)organsystems.
were similar (Table 1). The vast majority of all events were Three patients in the fidaxomicin arm developed megaco-
ratedasnotrelatedtostudydrugbytheinvestigators. lon,anunfortunatecomplicationofCDI.Onesubjectreceived
Rates for discontinuation of dosing due to an AE were also only 2 doses before his condition worsened. For the 2 other
comparableforbothdrugsinthephase3trials.Therewere33 subjects,megacolonwasdiagnosedwithatreatmentfailureon
of564(5.9%)and40of583(6.9%)subjectsinthefidaxomicin days 3and 6oftherapy,respectively.Onevancomycinsubject
and vancomycin arms, respectively, who stopped their treat- presentedwithalarge-intestineperforationonday31andwas
ment due to an AE (P=.48). Vomitingwasthe most frequent foundtohavetoxicmegacolonduringcolectomy.
AE leading to study drug discontinuation. This occurred for
0.5%ofsubjectsinbothtreatmentgroups[16].
HematologicSafety
Anemia was reported in 2% of both fidaxomicin and vanco-
GISafety
mycin subjects. Leukopenia (eg, decreases in white blood cell
Because the majority of fidaxomicin remains in the intestinal counts or neutrophils) were observed in 14 of 564 (2.5%) fi-
lumen and exerts its activity there, GI AEs in the fidaxomicin
daxomicin subjects and 6 of 583 (1.0%) vancomycin subjects
phase 3 studies were evaluated closely. In the phase 3 studies, (P=.06). There was no apparent explanation for this finding
thenumberofoverallGIAEsandSAEswassimilarbetweenthe
except that more patients received antineoplastic or immuno-
fidaxomicin and vancomycin groups. Slightly more GI AEs led modulating agents in the fidaxomicin group (11.9% vs 8.2%;
todiscontinuationfromthestudyinthefidaxomicingroupthan P=.04) [13]. Nearly all these reported events of leukopenia
inthevancomycingroup(2.3%vs1.4%;P=.24),butdeathsdue
occurred in subjects with underlying hematologic malignan-
to a GI AE tended to occur less frequently in the fidaxomicin
cies,recentbonemarrowtransplant,and/orrecentchemother-
groupthanthevancomycingroup(0.5%vs1.0%;P=.51). apy. No specific bone marrow toxicity was observed with
Some form of GI bleeding occurred in 23 fidaxomicin- fidaxomicin in the nonclinical studies [13]. The main clinical
treated patients (23 of 564; 4.1%) and 18 vancomycin-treated
concern regarding leukopenia is that it could lead to an in-
patients (18 of 583; 3.1%; P=.37). All GI bleeding events in
creased incidence of serious infections. However, it should
fidaxomicin subjects were deemed not related or unlikely
also be noted that no overall increased incidence of infections
related to the drug by the investigators. Also, many of these with fidaxomicin vs vancomycin was observed in the phase 3
studies (22.9% vs 20.8%, respectively). The incidence of infec-
tionsresulting indeathwas2.0% forfidaxomicinsubjectsand
Table1. AdverseEventsinPhase3Trials 1.9% for vancomycin subjects. No adverse effect on platelet
countswasobservedinnonclinicalorclinicalstudies.
Fidaxomicin, Vancomycin,
400mg(n= 500mg(n=
SubjectsWith≥1AE 564),No.(%) 583),No.(%) CardiacSafety
AnyAE 385(68.3) 382(65.5) Electrocardiograms(ECGs)wereobtainedbeforethefirstdose
AEsbyseverity and at the end of therapy. No significant changes in ECGs
Mild 160(28.4) 171(29.3) were observed during the study period. Therewere no signifi-
Moderate 117(20.7) 113(19.4) cant corrected QT (QTc) interval modifications for either
Severe 108(19.1) 98(16.8)
group in the phase 3 studies (Table 2). There was no associ-
AEsleadingtodiscontinuationof 33(5.9) 40(6.9) ation between QTc interval prolongation and increased fidax-
studydrug
AEsleadingtodosemodificationor 2(0.4) 8(1.4) omicin level. One patient receiving oral vancomycin in a
useofconcomitantmedication phase 3 trial developed torsades de pointes. Deaths due to
SeriousAEs 145(25.7) 135(23.2) cardiac events occurred in 0.4% of fidaxomicin subjects and
AEsresultingindeath 36(6.4) 38(6.5) 1.2% of vancomycin subjects (P=.18). In a subgroup analysis
Abbreviation:AE,adverseevent. with high plasma levels (fidaxomicin plus OP–1118 levels
(cid:129) (cid:129)
S112 CID 2012:55 (Suppl2) Weissetal
Table 2. Summary of 12-Lead Electrocardiogram Corrected QT Table 3. Summary Statistics for Changes in Liver Function Pa-
Interval Results (Bazett’s and Fridericia’s corrections): Phase 3 rametersBetweenBaselineandEndofTherapy:Phase3Studies
Studies
Fidaxomicin400 Vancomycin
Bazett’s Fridericia’s Parameter mg(n=564) 500mg(n=583)
ALT(U/L)
Fidaxomicin Vancomycin Fidaxomicin Vancomycin
QTc (n=501), (n=503), (n=501), (n=503), Patients,No. 482 478
intervals No(%) No.(%) No.(%) No.(%) Meanchange 6.1 −0.3
ChangesinQTcintervalfrombaseline(ms) SD 48.62 71.52
Medianchange 2 2
>30 42(8.7) 32(6.6) 37(7.7) 35(7.2)
Alkalinephosphatase(U/L)
>60 6(1.2) 6(1.2) 6(1.2) 5(1.0)
QTcintervalatendofstudy(ms) Patients,No. 502 506
Meanchange 3 2.7
>450 96(19.2) 109(21.7) 43(8.6) 54(10.7)
SD 59.07 47.19
>480 26(5.2) 34(6.8) 13(2.6) 16(3.2)
>500 12(2.4) 14(2.8) 7(1.4) 11(2.2) Medianchange −1 1
AST(U/L)
Onlysubjectswithbothbaselineandend-of-studyelectrocardiogramvalues
Patients,No. 473 459
areincludedinthisevaluation.
Meanchange 3 −4.5
Abbreviation:QTc,correctedQT.
SD 24.26 136.48
Medianchange 2 2
Bilirubin(mmol/L)
≥150ng/mL), there was no association between QTc interval Patients,No. 485 481
Meanchange −0.65 −0.92
prolongationanddruglevels.
SD 5.17 15.19
Medianchange 0 0
HepaticSafety
Directbilirubin(mmol/L)
In the phase 3 clinical studies, the incidence of AEs involving
Patients,No. 443 433
abnormalliverfunctiontest (LFT)resultswassimilarbetween Meanchange −0.33 −0.47
fidaxomicin and vancomycin (3.2% vs 2.6%; P=.53). No sig- SD 2.88 7.51
nificant changes in mean LFT results were observed in either Medianchange 0 0
group (Table 3). The numbers of subjects with normal LFT
Abbreviations:ALT,alanineaminotransferase;AST,aspartateaminotransferase;
results at baseline but a later LFT result at least 3 times the SD,standarddeviation.
upper limit of normal (ULN) were 6 for fidaxomicin and 5
for vancomycin. No subject in either group had an increase
inaspartateoralanineaminotransferaselevelto>3timesULN
UseinPregnancy
with an increase in bilirubin level >2 times ULN. Adverse
To date, there are no meaningful data available for fidaxomi-
events were also examined for subjects with and without ab-
cin use during pregnancy in humans. Onewoman with B-cell
normal LFT results at baseline. The overall incidence of AEs
was similar for fidaxomicin- and vancomycin-treated subjects lymphoma in a phase 3 study receiving fidaxomicin and also
receiving numerous other agents (including methotrexate and
withandwithouttheseabnormallaboratoryparameters.
vincristine) had a multiple-birth pregnancy. Her pregnancy
test was negative at enrollment and became positive on day
UseinRenalImpairment
25. She delivered 3 live and 1 dead fetuses; 1 female fetus was
No specific safety studies have been carried out to date with
foundtohaveacleftpalate.
fidaxomicin in subjects with renal or hepatic impairment.
However, 48% of subjects in the phase 3 studies had renal
insufficiency at baseline, and the safety of fidaxomicin was DISCUSSION
examinedinsubgroupsofsubjectswhohadvaryingdegreesof
renalinsufficiencybasedonestimatedcreatinineclearanceand In phase 3 trials, the overall safety profile of fidaxomicin was
characterized as either mild (51–79mL/min), moderate (31– comparablewiththatoforalvancomycin.Therewasnodiffer-
50mL/min),orsevere(≤30mL/min).Noclinicallysignificant enceintheincidenceofdeathsorSAEsbetweenthefidaxomi-
differences in the incidence of AEs between fidaxomicin and cin and vancomycin arms. There was a numerical imbalance
vancomycin subjects were observed within subpopulations inAEsrelatedtoGIhemorrhage(4.1%vs3.1%)andleukope-
withmild,moderate,orsevererenalinsufficiency. nia (4.1% vs 1.7%) between the fidaxomicin and vancomycin
(cid:129) (cid:129)
SafetyAnalysisofFidaxomicin CID 2012:55 (Suppl2) S113
groups, but no causal relationship between fidaxomicin and Bristol-Myers-Squibb, Genzyme Corp, GlaxoSmithKline, Optimer,
theseeventscouldbeestablished. Pharma,Pfizer,Roche,andTheravance.R.L.A.andS.S.arepaidconsult-
ants to Optimer Pharmaceuticals, Inc, regarding pharmacovigilance and
The oral formulation of vancomycin has been on the
pharmacoepidemiology,respectively.
market for >2 decades. Vancomycin can be administered to AllauthorshavesubmittedtheICMJEFormforDisclosureofPotential
children and pregnant women, and its long-term adminis- Conflicts of Interest. Conflicts that the editors consider relevant to the
contentofthemanuscripthavebeendisclosed.
tration as a therapy for recurrent CDI has not been linked to
any significant safety issues, with a long-term safety track
record unmatched by other drugs targeting CDI. Overall, the References
safety profile of vancomycin in CDI is consistent with the
1. Bartlett JG, Chang TW, Gurwith M, Gorbach SL, Onderdonk AB.
agent’s limited solubility and minimal systemic exposure after
Antibiotic-associated pseudomembranous colitis due to toxin-produ-
oraladministration.However,absorptionmaybefacilitatedby cingclostridia.NEnglJMed1978;298:531–4.
an inflamed gut, with increased potential for systemic side 2. TedescoFL,BartonRW,AlpersDH.Clindamycin-associatedcolitis:a
prospectivestudy.AnnInternMed1974;81:429–33.
effects [17]. Recently, a maculopapular rash induced by oral
3. McDonald LC, Owings M, Jernigan DB. Clostridium difficile in
vancomycinhasbeenreported[18]. patients discharged from US short-stay hospitals, 1996–2003. Emerg
The lower cost of metronidazole in comparison to vanco- InfectDis2006;12:409–15.
4. Kyne L, Hamel MB, Polavaram L, Kelly CP. Health-care costs and
mycin, the similar clinical effectiveness for mild to moderate
mortalityassociatedwithnosocomialdiarrheaduetoClostridiumdif-
disease, and the threat of VRE has favored the use of the ficile.ClinInfectDis2002;34:346–53.
former as first-line therapy for this type of patient. Oral met- 5. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-
ronidazole absorption is very high and potentially can lead to institutionaloutbreakofClostridiumdifficile–associateddiarrheawith
highmorbidityandmortality.NEnglJMed2005;353:2442–9.
more systemic side effects. Metronidazole has been linked to 6. Zilberberg MA, Shorr AF, Kollef M. Increase in adult Clostridium
several safety issues, including peripheral and optic neuropa- difficile–related hospitalizations and case-fatality rate, United States
thy [19, 20], and frequent less serious side effects (nausea, 2000–2005.EmergInfectDis2008;14:929–31.
7. Browne RA, Fekety R Jr, Silva J, Boyd DI, Work CO, Abrams GD.
tastedisturbance,andheadache).
Theprotectiveeffectofvancomycinonclindamycin-inducedcolitisin
Metronidazole is not approved by the FDA for the treat- hamsters.JohnsHopkinsMedJ1977;141:183–92.
ment of CDI. Drugs such as warfarin and lithium are known 8. BartlettJG.Thecaseforvancomycinasthepreferreddrugfortreatment
to interact, and alcohol must be avoided. The clinical efficacy ofClostridiumdifficileinfection.ClinInfectDis2008;46:1489–92.
9. Gerding DN. Is there a relationship between vancomycin-resistant
ofmetronidazolemaybelimitedformoreseverecasesandfor enterococcal infection and Clostridium difficile infection? Clin Infect
relapses[10]. Dis1997;25(Suppl2):S206–10.
Clostridium difficile infection is a growing concern for 10. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison
of vancomycin and metronidazole for the treatment of Clostridium
elderly frail patients who are disproportionately affected by difficile–associated diarrhea stratified by disease severity. Clin Infect
the disease and its related morbidity and mortality [6].Anti- Dis2007;45:302–7.
biotic stewardship is an interesting option to control CDI but 11. WenischC,ParschalkB,HasenhündlM,HirschlAM,GraningerW.
Comparison of vancomycin, teicoplanin, metronidazole and fusidic
has many limitations [21].A bundle approach in terms of in-
acidforthetreatmentofClostridiumdifficile–associateddiarrhea.Clin
fectioncontrolcanhaveasubstantialimpactonCDIratesbut InfectDis1996;22:813–8.
would not eliminate the issue [22]. Until recently, a limited 12. LouieTJ,MillerMA,MullaneKM,etal.OPT-80-003ClinicalStudy
Group.FidaxomicinversusvancomycinforClostridiumdifficileinfec-
numberoftherapeuticoptionswereavailable[23].
tion.NEnglJMed2011;364:422–31.
Thearrivaloffidaxomicinrepresentsamajoradditiontothe 13. Anti-Infective Drugs Advisory Committee. Dificid™ (fidaxomicin
CDI treatment armamentarium, a novel agent with a safety tablets)forthetreatmentofClostridiumdifficileinfection(CDI),also
profile comparable with vancomycin in clinical trials. As with known as Clostridium difficile–associated diarrhea (CDAD), and for
reducing the risk of recurrence when used for treatment of initial
all new drug introductions and in particular with novel drugs,
CDI. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/
carefulandcontinuoussurveillanceandmonitoringinthepost- CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisory
marketingsetting willaugment the presentpremarketing safety Committee/UCM249354.pdf.Accessed11November2011.
14. ShueYK,SearsPS,ShangeS,etal.Safety,tolerance,andpharmacoki-
experience and contribute to further understanding of the
netic studies of OPT-80 in healthy volunteers following single and
safetyoffidaxomicinduringroutineclinicaluse. multipleoraldoses.AntimicrobAgentsChemother2008;52:1391–5.
15. Louie T, Miller M, Donskey C, Mullane K, Goldstein EJC. Clinical
Notes outcomes,safety,andpharmacokineticsofOPT-80inaphase2trial
with patients with Clostridium difficile infection. Antimicrob Agents
Supplement sponsorship. This article was published as part of a Chemother2009;53:223–8.
supplement entitled “Fidaxomicin and the Evolving Approach to the 16. GorbachS,WeissK,SearsP,PullmanJ.Safetyoffidaxomicinversus
Treatment of Clostridium difficile Infection,” sponsored by Optimer vancomycin in treatment of Clostridium difficile infection [poster
Pharmaceuticals,Inc. L1-1640].In:Programandabstractsofthe49thAnnualInterscience
Potential conflicts of interest. K. W. received research grants Conference on Antimicrobial Agents and Chemotherapy (San Fran-
from Health-Canada, Valorisation Recherche Quebec, Abbott, Bayer, cisco).Washington,DC:ICAAC,2009.
(cid:129) (cid:129)
S114 CID 2012:55 (Suppl2) Weissetal
17. Aradhyula S, Manian FA, Hafidh SA, Bhutto SS, Alpert MA. 21. OwensRC, Donskey CJ,Gaynes RP, Loo VG, MutoCA. Antimicro-
Significant absorption of oral vancomycin in a patient with Clostri- bial-associated risk factors for Clostridium difficile infection. Clin
dium difficile colitis and normal renal function. South Med J 2006; InfectDis2008;46(Suppl1):S19–31.
99:518–20. 22. Weiss K, Boisvert A, Chagnon M, et al. Multipronged intervention
18. OsawaR,KakaAS.Maculopapularrashinducedbyoralvancomycin. strategytocontrolanoutbreakofClostridiumdifficileinfection(CDI)
ClinInfectDis2008;47:860–61. anditsimpactontheratesofCDIfrom2002to2007.InfectControl
19. DuffyLF,DaumF,FisherSE,etal.PeripheralneuropathyinCrohn’s HospEpidemiol2009;30:156–62.
disease patients treated with metronidazole. Gastroenterology 1985; 23. ViroPharma Inc. VancocinHClcapsules (vancomycin hydrochloride
88:681–4. capsules, USP) [prescribing information]. Available at: http://www.
20. McGrath NM, Kent-Smith B, Sharp DM. Reversible optic neuropathy vancocin.com/~/media/Vancocin/Files/Vancocin_PI.ashx. Accessed
duetometronidazole.ClinExperimentOphthalmol2007;35:585–6. 14November2011.
(cid:129) (cid:129)
SafetyAnalysisofFidaxomicin CID 2012:55 (Suppl2) S115